Antibody Evaluation
Antibody Evaluation - Related Videos
04:59
Evaluating the Intracellular Distribution of Virus-Derived Peptide-Modified Antibody Conjugates
0 Views •
2025
This video demonstrates the process of assessing the intracellular distribution of virus-derived peptide-modified antibody conjugates using confocal microscopy. The viral-derived nuclear localization sequence directs antibody-conjugates within the cytoplasm, confirmed through immunostaining and fluorescence measurement.
03:54
An In Vitro Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilm
0 Views •
2025
This video demonstrates an in vitro technique to study the effect of antibodies on fungal biofilms. The pathogenic fungus Candida tropicalis secretes a virulence factor secreted aspartyl proteinase 2 (Sap2), facilitating biofilm formation. Upon introducing a heat-inactivated serum containing Sap2-specific antibodies that inhibit biofilm maturation, the viability of the fungal cells is assessed using a chromogenic assay.
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
11:58
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
0 Views •
Cited by 5 •
2018
Viral-derived peptides coupled to antibody-conjugates (ACs) is an approach gaining momentum due to the potential of delivering molecular payloads with increased tumor cell accumulation. Utilizing common methods to evaluate peptide conjugation, AC and payload intracellular accumulation, and tumor targeting, this protocol helps researchers during the key initial development phases.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
FAQs
Specificity indicates whether an antibody recognizes the intended target rather than unrelated targets, whereas affinity describes the strength of that binding. Biological activity adds a separate functional dimension, such as neutralization or receptor blocking. Evaluating these properties together helps distinguish an antibody that binds an antigen from one that binds selectively and produces the desired biological effect.
Cross-reactivity occurs when an antibody recognizes targets beyond the intended antigen, which can make binding results difficult to interpret. This issue matters in diagnostic and infection studies because apparent recognition may not reflect selective target detection. Comparing results across appropriate assays can reveal whether observed binding represents intended specificity or a limitation of the antibody.
ELISA, immunoblotting, flow cytometry, and surface-based binding assays can provide different evidence about antigen recognition and binding behavior. Functional tests examine consequences that binding assays do not establish, including neutralization or receptor blocking. Using more than one approach can therefore connect target recognition with antibody performance while exposing assay-dependent limitations.
A practical workflow begins by measuring recognition of the intended antigen, then examines specificity and affinity, and finally tests relevant biological activity when required. Results should also be reviewed for cross-reactivity, variability, and assay limitations. This sequence helps determine whether an antibody is suitable for its intended research or clinical purpose rather than relying on a single measurement.
The approach supports validation of diagnostic antibodies, characterization of immune responses, comparison of vaccine-induced and infection-induced antibodies, and identification of therapeutic candidates. These uses require different emphasis: diagnostic work depends on reliable target recognition, immune-response studies support comparisons between antibody groups, and therapeutic development requires attention to functional effects such as neutralization or receptor blocking.
Testing antibodies from vaccine-induced and infection-induced responses with comparable recognition and functional measurements can reveal differences in target binding and biological activity. Such comparisons may include specificity, affinity, neutralization, or receptor blocking, depending on the study objective. Interpreting the results requires attention to assay variability and limitations so that apparent differences are not attributed incorrectly to the immune source.